The ALZEVIT study is conducted by FIRALIS S.A, a French biotechnology company founded in 2008 and based in Huningue, in the Grand Est region of France.
Firalis specialises in the development of innovative biomarkers and precision diagnostic solutions, mainly in the fields of neurological, cardiovascular and inflammatory diseases.
The company works with many institutional and academic partners, both in France and internationally, and carries out applied and translational research projects recognised at European level.
Certified, integrated facilities
Firalis has its own biological sample collection centre, approved and certified by the Regional Health Agency (ARS), which guarantees that samples are collected in strict compliance with quality, safety and ethical standards.
The company also has its own biobank, integrated within Firalis,
ensuring optimal storage and traceability of the biological samples
collected as part of its studies.
These in-house facilities provide full control over the entire value chain,
from sample collection through to analysis and the scientific use of the data.
Our past and current clinical studies
Our clinical studies
Firalis regularly conducts clinical studies to validate its diagnostic tools and to advance research into innovative biomarkers.
ADDIA, a European multicentre study conducted by Amoneta Diagnostics, dedicated to the development and validation of new blood biomarkers for the early detection of Alzheimer’s disease, in partnership with several European research centres and hospitals.
These projects reflect Firalis’ ongoing commitment to rigorous, ethical and innovative clinical research, in the service of precision medicine and public health.
A supervised, ethical and secure study
Proven clinical study management
Firalis has a solid track record in managing clinical studies, with ISO 9001 and ISO 13485 certified facilities and teams experienced in handling, analysing and securing biological and personal data.
GDPR
The ALZEVIT study complies with the GDPR (General Data Protection Regulation).
CNIL
It has been declared to the CNIL (the French data protection authority).
Secure system
Data are hosted on a secure system certified for health data hosting.
Consent
Participants’ consent is collected securely and in accordance with the requirements of the ethics committee (Comité de Protection des Personnes, CPP).